ADIM
KRYS icon

Alpha DNA Investment Management’s Krystal Biotech KRYS Stock Holding History

Alpha DNA Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,332
Closed -$424K – 225
2024
Q3 		$424K Sell
2,332
-226
-9% -$43.6K 0.16% 161
2024
Q2 		$470K Sell
2,558
-413
-14% -$69.3K 0.18% 126
2024
Q1 		$529K Buy
+2,971
New +$413K 0.2% 126

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alpha DNA Investment Management's KRYS Position: Q4 2024 in Review

Alpha DNA Investment Management sold out of Krystal Biotech (KRYS) in Q4 2024, closing a stake of 2,332 shares — an estimated $424K sold.

Alpha DNA Investment Management first reported a position in KRYS in Q1 2024 and held it in 3 quarters. The position peaked at $529K in Q1 2024. 264 funds tracked by Wall St. Rank hold KRYS as of Q4 2024.

  • Alpha DNA Investment Management reported no remaining Krystal Biotech position as of Q4 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 2,332 Krystal Biotech shares in Q4 2024, an estimated $424K.
  • Alpha DNA Investment Management first reported a position in Krystal Biotech in Q1 2024 and held it in 3 quarters.
  • Alpha DNA Investment Management's Krystal Biotech position peaked at $529K in Q1 2024.
  • 264 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2024.

Based on Alpha DNA Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.